比较半剂量四联单胶囊与标准剂量双联初始治疗高血压患者(QUADUAL)的随机盲法交叉试验统计分析方法计划
QUADUAL试验为随机双盲交叉临床研究,比较半剂量四联单胶囊(厄贝沙坦75 mg+美托洛尔23.75 mg+氨氯地平2.5 mg+吲达帕胺1.25 mg)与标准剂量双联(厄贝沙坦150 mg+氨氯地平5 mg)在轻中度高血压(140-179/90-109 mmHg)初始治疗中的疗效与安全性,计划纳入90例受试者按1:1随机分配至两个交叉组,主要结局为动态血压监测的平均24小时收缩压,采用线性混合效应模型分析。本统计分析方法计划旨在提高QUADUAL试验的有效性。
要点
- 两组分别接受4周不同联合治疗,经过2周洗脱期后交换至另一方案再治疗4周。
- 主要结局为动态血压监测的平均24小时收缩压,采用线性混合效应模型评估。
- 计划纳入90例轻中度高血压患者,按1:1随机分配至两个交叉组。
核心结论
- 本统计分析方法计划将在盲态审核和数据锁定前确认,旨在提高QUADUAL试验的有效性。
研究设计与样本
- 随机双盲交叉临床试验,计划纳入90例轻中度高血压(140-179/90-109 mmHg)患者,按1:1随机分配至两个交叉组。
- 两组先接受一种联合治疗4周,经过2周洗脱期后交换至另一种联合治疗4周。
主要发现
- 原文未报告结果。
关键数值与推荐
- 半剂量四联方案:厄贝沙坦75 mg+美托洛尔23.75 mg+氨氯地平2.5 mg+吲达帕胺1.25 mg。
- 标准剂量双联方案:厄贝沙坦150 mg+氨氯地平5 mg。
- 主要结局为动态血压监测的平均24小时收缩压,采用线性混合效应模型分析。
- 计划样本量为90例,按1:1随机分配至两个交叉组。
- 洗脱期为2周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combined antihypertensive therapy has obvious advantages over single drug therapy. Hypertension guidelines fully affirm the efficacy of dual combination in initial antihypertensive therapy. Recent studies have also pointed out that the quadruple combination of very low-dose antihypertensive drugs is superior to single drugs. However, whether low-dose quadruple therapy is better than dual combination is unknown. METHODS/DESIGN: A randomized double-blind crossover clinical trial will be conducted to compare the efficacy and safety of low-dose quadruple antihypertensives (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg) with standard-dose dual antihypertensives (irbesartan 150 mg + amlodipine 5 mg) in the initial treatment of patients with mild to moderate hypertension (140-179/90-109 mmHg). Ninety patients are required and will be recruited and randomly assigned in a 1:1 ratio to two crossover groups. Two groups will receive a different combination therapy for 4 weeks, then switch to the other combination therapy for 4 weeks, with a 2-week wash-out. Antihypertensive effects and related adverse effects of the two antihypertensive combination treatments will be compared. The primary outcome, i.e., mean 24-h systolic blood pressure in ambulatory blood pressure monitoring, will be assessed via linear mixed-effects model. DISCUSSION: This statistical analysis plan will be confirmed prior to blind review and data lock before un-blinding and is sought to increase the validity of the QUADUAL trial. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05377203. Registered May 11, 2022, https://clinicaltrials.gov/study/NCT05377203 .
引用
- Zhao X, Li X, Liu T, et al. Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial. Trials. 2024. PMID: 38218924. doi:10.1186/s13063-023-07803-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。